Novartis’ MF59 Vaccine Shows Efficacy in Avian Flu

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

A new study of Novartis’ MF59-adjuvanted vaccine showed that it rapidly induced protective antibody levels against diverse strains of avian flu. In the study, individuals immunized six years earlier with an MF59 adjuvanted H5N3 (clade 0) vaccine mounted a protective immune response seven days after a single immunization with an H5N1 (clade 1) vaccine containing Novartis’ adjuvant MF59. The immune response was broadly cross reactive and covered all H5N1 clades known to date.       ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters